Skip to content

More than prevention: PrEP enhances income, trust, and intimacy in Uganda

Kampala. Image by Nao Lizuka. Creative Commons licence.

Most male partners of women using the dapivirine vaginal ring support its use in HIV prevention

Image credit: NIAID. Creative Commons licence.

Not all PrEP programmes are screening for STIs

Mufid Majnun/Unsplash

Top 5 stories on injectable HIV treatment and prevention from CROI 2021

Professor Raphael Landovitz presenting findings on injectable PrEP to CROI 2021.

Top 5 stories on HIV treatment and care in Africa from CROI 2021

Professor Nicholas Paton (bottom, left) presenting the study on second-line treatment to CROI 2021.

PrEP does not lower hormone levels in young transgender people, but lower PrEP levels seen in some transgender women

A young transgender woman looking in the bathroom mirror. The Gender Spectrum Collection. Image is for illustrative purposes only.

Injectable HIV medications must be practical and affordable, conference hears

Carlos del Rio, Diane Havlir, Charles Flexner, Francois Venter, Hyman Scott, Nittaya Phanuphak (top to bottom, left to right) at CROI 2021.

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

Slide from Dr Anne Neilan's presentation to CROI 2021. Diagram shows prices of two different forms of PrEP where injectable PrEP is not cost-effective (red); cost-effective (yellow); and cost-saving (green).

Social networks key to PrEP uptake in rural Kenya and Uganda

Dr Catherine Koss (bottom left) presenting to CROI 2021.